The global anti-osteoporosis therapy and fracture healing market is expected to attain a valuation of USD 14,051.6 million in 2023. The market is projected to reach USD 22,427.6 million by 2033, anticipated to expand at a CAGR of 4.8% during the forecast period.
The market for osteoporosis treatment is expected to experience growth due to the increasing prevalence of the disease and an increase in the number of affected patients. Key players are primarily focusing on the geriatric population which is helping the market to grow. Additionally, prevalence of bone diseases is also contributing to market growth. Increasing research and development expenditure aimed at generating new drugs is further anticipated to induce growth in the market.
The growing awareness about the diagnosis and treatment of osteoporosis is contributing to the expansion of the market. Additionally, an increase in healthcare facilities such as trauma centers is also driving the growth of the anti-osteoporosis therapy and fracture healing market. Increasing investments in research and development activities for generation of drugs and growing awareness about osteoporosis are also adding to the growth of osteoporosis treatment market.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 14,051.6 million |
| Anticipated Forecast Value (2033) | USD 22,427.6 million |
| Projected Growth Rate (2023 to 2033) | CAGR 4.8% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The anti-osteoporosis therapy and fracture healing market was worth USD 11,048.3 million in 2018. It accumulated a market value of USD 13,442.0 million in 2022. During the historical period from 2018 to 2022, a CAGR of 4.0% was observed.
The global market for anti-osteoporosis therapy and fracture healing is expected to experience continuous growth in the coming years due to the rapid expansion of the healthcare industry and increased healthcare expenditure in emerging economies like China and India. The rising benefits of anti-osteoporosis therapies over other treatments for osteoporosis are also expected to sculpt market growth over the forecast period.
The approval of anti-osteoporosis therapy and fracture healing drugs and injectables by the United States Food and Drug Administration is expected to intensify competition among market players which could more likely aid in market expansion.
Many companies are prioritizing the development of advanced products that are easy to use and offer rapid efficacy in the treatment of osteoporosis. For example, Amgen Inc. announced in April 2019 that its EVENITY® had received approval from the United States Food and Drug Administration (FDA) for the treatment of postmenopausal women at high risk of fracture.
Forteo and other companies have demonstrated significant increases in lumbar spine bone mineral density compared to alendronate. Bisphosphonates and estrogen therapy, on the other hand, have chronic side effects such as jaw death, vaginal bleeding, and uterus cancer, highlighting the need for new drugs with fewer or no side effects.
Selective estrogen receptor modulators (SERM) drugs like Evista and Duavee were developed to address estrogen's side effects. The anti-osteoporosis therapy and fracture healing market is projected to be worth USD 22,427.6 million by end of the forecast period while exhibiting a CAGR of 4.8%.
Rising Demand for Non-invasive Therapies to Drive Market Growth
The increasing prevalence of osteoporosis is a key factor driving the global market, as a growing number of patients is expected to drive up demand for drugs and therapy. Additionally, there are no substitutes such as surgery, so the demand for osteoporosis treatment drugs is expected to rise.
The International Osteoporosis Foundation predicted that nearly 50% of global bone fracture incidences will occur in the Asia Pacific region by the end of 2050. The high occurrence and incidence rate of the disease are significant drivers for the market. In addition, the increasing geriatric population is expected to drive market growth in the coming years, although patent expirations of leading brands are likely to considerably slow down the growth rate.
The increasing prevalence of osteopenia and osteogenesis imperfecta (OI) is expected to drive demand for products over the forecast period. The market is also being propelled by the introduction of advanced products and technological advancements.
According to the National Osteoporosis Foundation, calcium deficiency is a major contributor to the increased prevalence of osteoporosis in postmenopausal women. This has become a key driver for anti-osteoporosis therapy and fracture healing demand.
The rising demand for non-invasive therapies is further contributing to the market expansion. Pharmaceutical companies are expected to prioritize improving their production capabilities. The scientific progress made in enhancing product effectiveness and reducing complications has led to increased investment in innovation and the introduction of new products. These efforts are expected to fuel the expansion of the anti-osteoporosis and fracture healing market during the forecast period.
Principal Consultant
Complications During Disease Treatment to Restrain Market Growth
The market growth is likely to be hindered by the occurrence of complications during the disease treatment such as ulcers, irritable bowel syndrome, and nausea.
North America Driving growth at a Significant Pace
The North American anti-osteoporosis therapy and fracture healing market accounted for a revenue share of 33.5% in 2022. The United States alone accounted for a revenue share of 30.1% in the same year. The entire region is expected to grow with a CAGR of 4.5% during the forecast period.
The region is expected to remain at the forefront of the market due to the increased investment in research and development for the development of new drugs, a growing geriatric population, and a rising incidence of diseases resulting from changing lifestyles.
The increasing adherence to regulatory standards is further inducing growth in the regional market. With greater acceptance and commercialization of anti-osteoporosis therapy and fracture healing drugs in the United States, the demand for these treatments is expected to increase.
Most of the major players in the global anti-osteoporosis and fracture healing markets have their headquarters in the United States, creating opportunities for new markets in diagnosis and care. Also, the relatively higher cost of medications in countries like the United States enables a high-profit margin for the businesses to operate there.
Asia Pacific Driving Growth with a Significant CAGR
The Asia Pacific anti-osteoporosis therapy and fracture healing market is expected to grow with a significant CAGR of 4.3% from 2023 to 2033. The markets in China and India are projected to grow with a CAGR of 4.6% and 4.4% respectively during the forecast period.
The demand outlook in this region is expected to thrive at a significant rate in the forecast period, with India and China expected to remain most promising markets in the region. Some of the key factors driving the market growth in developing countries include increasing awareness about osteoporosis, a large pool of patients, a rising incidence of the geriatric population, changing lifestyles, and increasing healthcare expenditure.
China, being one of the most populous countries across the globe, is considered to have substantial growth potential in the anti-osteoporosis and fracture healing market. In addition, over the past decade, China has expanded its manufacturing capability, emerging as the leading supplier of drugs and raw materials in this market.
Malaysia is anticipated to be the second-largest market in South Asia for anti-osteoporosis treatment and fracture healing, following India. The market is projected to grow at a rate of over 3.1%. Malaysia is also an attractive destination for medical tourism due to its comparatively lower healthcare costs than the United States and the United Kingdom.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Bisphosphonates driving growth with a sizeable market share
Bisphosphonates segment accounted for a revenue share of 49.2% in 2022. This segment is expected to dominate the market while growing a CAGR of 6% during the forecast period. The increase in demand for targeted therapeutics and a shift in prescribing patterns towards bisphosphonates are contributing factors to segment growth.
Bisphosphonates are a type of medication that can slow down bone resorption, reducing the likelihood of spine and hip fractures. Although the process of bone regeneration is gradual, many patients may observe an improvement in bone density after five years of treatment with these drugs. Bisphosphonates are effective in treating various solid tumors affecting bones, such as multiple myeloma, by reducing skeletal morbidity.
These medications are increasingly being used in combination with anticancer therapies to prevent skeletal problems and alleviate bone pain. These factors are anticipated to keep the demand for bisphosphonate stable throughout the forecast period.
Oral Anti-Osteoporosis Therapy and Fracture Healing Drugs to be Most Preferred
Oral anti-osteoporosis therapy and fracture healing drugs accounted for a revenue share of 64.8% in 2022. The segment is expected to grow at a CAGR of 6.2% from 2023 to 2033.
Non-invasive therapeutics for anti-osteoporosis treatment and fracture healing are available in both oral and injectable forms. The oral drug segment is expected to capture over 65% of market share by end of 2023, as there is a rising demand for non-invasive therapies. Factors such as the increasing prevalence of needle phobia and needle stick injuries are expected to drive the demand for oral therapeutics.
The dominance of oral drugs in the market can be attributed to their convenience and wider availability in various regions. Compared to injectable treatment, oral drugs are more cost-effective and do not require the presence of nursing staff for administration. The increasing use of bisphosphonates for osteoporosis treatment is a significant driver of growth for the oral drug segment.
Start-ups have a significant role in recognizing potential growth prospects in any market. They are capable of generating high returns, which benefits the industry's expansion. Start-ups are generally more effective in converting inputs into outputs and are more flexible and adaptable to unstable market conditions. Below are some of the start-ups that are anticipated to drive growth in the anti-osteoporosis therapy and fracture healing market:
The anti-osteoporosis therapy and fracture healing market is extremely competitive and consists of various key industry players. These players are heavily investing in anti-osteoporosis therapy and fracture healing drugs market.
Key industry players are: Eli Lilly and Company, Pfizer, Inc, Amgen Inc., Merck, and Company Inc., Novartis International AG, F. Hoffmann La Roche Ltd., Teva Pharmaceuticals Industries Ltd., GlaxoSmithKline Plc., Sanofi S.A., Johnson & Johnson
Some recent developments in the market are:
Key industry players leverage organic growth strategies like acquisition, mergers, partnerships, and collaboration to enhance their product portfolio. This is expected to fuel the global anti-osteoporosis therapy and fracture healing market.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 14,051.6 million |
| Market Value in 2033 | USD 22,427.6 million |
| Growth Rate | CAGR of 4.8% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
Drug Type, Route of Administration, Distribution Channel, Region |
| Regions Covered |
North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa |
| Key Countries Profiled |
United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, China, Japan, South Korea, India, Malaysia, Singapore, Thailand, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled |
Eli Lilly and Company; Pfizer Inc.; Amgen Plc.; Merck and Company Inc.; Novartis AG; F. Hoffmann La Roche Ltd.; Teva Pharmaceuticals Industries Ltd.; GlaxoSmithKline Plc.; Sanofi S.A.; Johnson & Johnson |
| Customization & Pricing | Available Upon Request |
North America is projected to emerge as a lucrative market.
The growth potential of the global market is 4.8% through 2033.
The rising complications during treatment is likely to limit market growth.
The United States is likely to secure a CAGR of 30.1% in 2023.
The market is estimated to secure a valuation of USD 14,051.6 million in 2023.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type 5.1. Bisphosphonates 5.2. Calcitonin 5.3. Hormone Replacement Therapy 5.4. Others 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Oral 6.2. Injectable 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Hospital Pharmacies 7.2. Drug Stores 7.3. Retail Pharmacies 7.4. E-commerce 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. South Asia 8.5. East Asia 8.6. Oceania 8.7. MEA 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. Eli Lilly and Company 18.2. Pfizer, Inc. 18.3. Amgen Inc. 18.4. Merck and Company Inc. 18.5. Novartis International AG 18.6. F. Hoffmann La Roche Ltd. 18.7. Teva Pharmaceuticals Industries Ltd. 18.8. GlaxoSmithKline Plc. 18.9. Sanofi S.A. 18.10. Johnson & Johnson 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Anti-Osteoporosis Therapy and Fracture Healing Market
